The analyst team at Morgans believe the shares are deeply undervalued at this point, and has a very bullish share price target on the company which I'll get to shortly.

First let's have a look at a recent announcement on the company's business.

Solid progress on take-up of technology

EBR has developed a system called WiSE which it says is designed to overcome the limitations of conventional cardiac resynchronisation therapy and, "is the only leadless left ventricular endocardial pacing (LVEP) device".

The company recently released a quarterly report and said that it had surpassed its hundredth commercial WiSE implant, "with multiple sites performing their first WiSE implants and numerous sites performing their 2nd, 3rd, 4th, and greater cases".

EBR Chief Executive Officer John McCutcheon said:

We are extremely pleased with this quarter on multiple fronts. Commercially, EBR surpassed its 100th commercial WiSE implant, with multiple sites performing their first WiSE implants and numerous more experienced sites continuing to treat patients with WiSE. We secured master purchasing agreements with HCA Healthcare, Advocate Health, and CHRISTUS Health, validating the clinical and economic benefit of WiSE in major U.S. healthcare networks. In support of our future commercial efforts, the U.S. Centers for Medicare & Medicaid Services (CMS) further advanced WiSE through the Transitional Coverage for Emerging Technology (TCET) program by formally initiating the National Coverage Determination process for WiSE.

The company also fully transitioned to its new manufacturing facility in California, Mr McCutcheon said.

During the quarter, EBR had operating cash outflows of $25 million, but also completed a $150 million capital raise.

Shares in this ASX biotech looking very cheap

Morgans said in its note to clients issued this week that they believed the commercial roll out, "has progressed further than the headline implant numbers suggest, but execution capacity has temporarily become a key variable''.

Morgans added:

Management is now deliberately de-emphasising new site contracting and physician training to focus on repeat utilisation within existing accounts. This should reduce the administrative burden on the field organisation and allow trained representatives to spend more time supporting procedures. Thus, we view implant productivity per activated account rather than the number of contracted hospitals as the key near-term variable. With 17 sites already having completed ≥3 cases, we see an opportunity for utilisation to compound as physicians gain experience and WiSE becomes embedded in clinical workflows.

Morgans said the company had moved beyond the question of whether hospitals would buy WiSE, to proving whether they could generate repeat sales.

They added, "we view the existing footprint as adequate to provide substantial gains not reflected in the current share price''.

Morgans has a share price target of $1.95 on EBR shares compared to 30.5 cents currently.

The company is valued at $214.7 million.

The post Could this ASX biotech really jump more than 500%? appeared first on The Motley Fool Australia.

Naturally this begs the question, are they cheap at the moment?

The analyst team at Bell Potter thinks so and has a speculative buy recommendation on the company, along with a bullish share price target, which I'll get to shortly.

First let's look at what the company has been up to.

Solid progress on technology sales

EBR has developed a system called WiSE which it says is designed to overcome the limitations of conventional cardiac resynchronisation therapy and, "is the only leadless left ventricular endocardial pacing (LVEP) device''.

The company recently released a quarterly report and said that it had surpassed its hundredth commercial WiSE implant, "with multiple sites performing their first WiSE implants and numerous sites performing their 2nd, 3rd, 4th, and greater cases''.

The company also completed the first two tranches of a fully underwritten $150 million capital raise with the final $35 million expected to be completed by August 24.

EBR Chief Executive Officer John McCutcheon said:

We are extremely pleased with this quarter on multiple fronts. Commercially, EBR surpassed its 100th commercial WiSE implant, with multiple sites performing their first WiSE implants and numerous more experienced sites continuing to treat patients with WiSE. We secured master purchasing agreements with HCA Healthcare, Advocate Health, and CHRISTUS Health, validating the clinical and economic benefit of WiSE in major U.S. healthcare networks. In support of our future commercial efforts, the U.S. Centers for Medicare & Medicaid Services (CMS) further advanced WiSE through the Transitional Coverage for Emerging Technology (TCET) program by formally initiating the National Coverage Determination process for WiSE.

The company also fully transitioned to its new manufacturing facility in California, Mr McCutcheon said.

During the quarter EBR had operating cash outflows of $25 million.

Shares are looking cheap but more capital needed

In a note to clients released after the quarterly results, Bell Potter said that EBR's cash receipts were still modest at US$3.6 million for the quarter but had doubled in the period. Bell Potter also noted that the company has five quarters' worth of cash on hand.

The broker believes the company will need to raise more capital, and has therefore reduced its share price target on EBR to 70 cents, down 22%. This is still well above the current share price of 28 cents.

The broker added:

This still represents significant upside potential, but the need for more funding may weigh on investor sentiment. We retain our BUY (Spec.) rating.

EBR is valued at $214.7 million.

The post Bell Potter tips more than 140% upside for this out of favour ASX biotech appeared first on The Motley Fool Australia.

Yesterday, the company released an announcement that it aims to raise A$150.0m via a fully underwritten capital raising. 

According to the release, the proceeds from the Capital Raising are intended to be used to support sales and marketing expansion, manufacturing scale up, R&D and clinical, working capital and the costs of the offer.

The offer price per New CDI (Offer Price) under the Capital Raising is 38 cents. This represents a 19.1% discount to the last closing price of EBR on June 3 which was 47 cents per share. 

EBR company overview

EBR is a clinical stage company that has developed its patented Wireless Stimulation Endocardially (WiSE) technology. The technology is for the treatment of cardiac rhythm disease and to eliminate the need for cardiac pacing leads when delivering cardiac resynchronisation therapy.

It has been hotly covered over the last few months as it has repeatedly received positive outlooks from brokers. 

However, this is yet to translate to realised capital gains. Its share price has fallen almost 50% year to date. 

What does this mean for investors?

For investors, this capital raise is a significant dilution event for this ASX small-cap. 

EBR is issuing a large number of new shares at a heavily discounted price. This means existing shareholders who do not participate in the entitlement offer will see their ownership percentage reduced. 

The raise price of 38 cents per share may also put short-term pressure on the share price as the market adjusts to the new valuation.

However, the positive side is that EBR has secured more capital than expected. Management believes this funding should carry the company through to cash-flow breakeven, reducing the risk of further capital raisings in the future. 

The funds will also allow the company to accelerate sales, marketing, manufacturing and clinical activities.

Overall, investors are being asked to accept substantial near-term dilution in exchange for a stronger balance sheet, a potentially lower need for future fundraising, and an improved pathway to commercial success. 

The investment case now depends more heavily on whether EBR can execute its growth strategy and convert this into meaningful sales over the next few years.

What's Bell Potter's view?

Following the announcement, the team at Bell Potter also weighed in on the outlook for this ASX small-cap. 

The broker appears to be cautiously positive on the business, but disappointed by the terms of the capital raise.

The A$150m raise is larger than expected. This is not necessarily a negative because it gives EBR more funding to execute its commercialisation strategy.

However, the dilution is materially worse than they anticipated. 

They specifically highlighted that the share count will increase by about 87.6% and that the issue price of 38 cents is far below their assumed 63 cents. This reflects how much the share price had weakened before the raise.

Despite this, the broker has retained its buy recommendation and $2.00 price target. 

This indicates an upside potential of more than 325%. 

We view the raising as a significant de-risking event, enabling EBR to commercialise WiSE and reach breakeven by FY29. 

This raising should serve as a cathartic event and clear the overhang from the share price. Post shareholder approval of tranche 2, we think the share price will be well supported by the market.

The post ASX small-cap with 300%+ potential upside announces capital raise appeared first on The Motley Fool Australia.

Their lower market valuations, earlier growth stage, and thinner analyst coverage mean successful execution or new capital flows can re-rate them much faster than large established companies.

Here are two that have received updated guidance from the team at Bell Potter. 

Accent Group Ltd (ASX: AX1)

Accent Group Limited is a footwear and sports clothing retailer and wholesaler which owns/operates a number of footwear businesses in the performance, comfort and active lifestyle sectors. 

These include multi-branded retailers, The Athlete's Foot (TAF) Australia, Platypus, Hype, Sports Direct and Glue Store, as well as a number of mono-branded retail stores for Merrell, Skechers, Vans, Timberland, Stylerunner, and more. 

While AX1 has a dominant market position in the overall Australian footwear market, the company also has an emerging presence in youth apparel through its Glue Store platform.

This ASX small-cap has struggled year to date, falling 42% in that span. 

Bell Potter recently updated their outlook on the company following a recent trading update. 

The broker noted that Accent Group revised down their FY26 EBIT guidance to $79.5-84.5m (was $85-95m). 

The investor day on 13th May focused on company's Vision 2030, which should see a stronger position in the sports category from the diversification via the addition of 30 Sports Direct (SD) stores over the next 3 years and further growth in their vertical brands division led by a strong business, while maintaining lifestyle category market share (BPe market share ~30% in Australia).

The broker subsequently lowered its price target to 60 cents per share for this ASX small-cap (previously 68 cents). This is just slightly above the current share price of 55 cents.

It maintained its hold recommendation. 

EBR Systems Inc (ASX: EBR)

EBR Systems develops implantable systems for wireless tissue stimulation.

Its share price has also fallen significantly in 2026, down 44% year to date. 

However, Bell Potter is projecting significant growth for this ASX small-cap. 

In a recent report, it said the company is trading at an attractive entry point.

It noted that In the last week, EBR has announced hospital purchase agreements with 325 hospitals and thousands of other health centres, covering a large swathe of the US.

These groups are also amongst the largest hospital groups in the US, reflecting validation of the WiSE-CRT system.The agreements pave the way for EBR sales reps to directly engage with individual physicians within these groups to generate adoption and build clinical traction.

The broker has retained its buy recommendation and $2 price target on this ASX small-cap. 

From yesterday's closing price, this indicates an upside potential of 286%. 

The post Bell Potter tips nearly 300% upside for one of these ASX small-caps appeared first on The Motley Fool Australia.

Fresh price targets from experts indicates this could be a rare opportunity for investors. 

The company develops implantable systems for wireless tissue stimulation. Its WiCS Wireless Cardiac Stimulation technology helps address the significant opportunity to eliminate cardiac pacing leads.

Brokers have been dropping fresh guidance on the ASX biotech stock after it secured a purchasing agreement with HCA Healthcare, one of the largest healthcare systems in the US, representing an important commercial milestone. 

What did the company report?

On Wednesday, the company released an announcement to the ASX that it has secured a purchasing agreement with HCA Healthcare, marking a significant step in the commercial rollout of its WiSE CRT System.

HCA Healthcare is one of the largest healthcare networks in the U.S., with 190 hospitals and approximately 2,500 ambulatory sites of care across 19 states.

John McCutcheon, EBR Systems' President & Chief Executive Officer said:

Securing a purchasing agreement with HCA Healthcare is an important commercial milestone for EBR. Establishing a purchasing pathway across one of the largest healthcare networks in the U.S. supports broader commercial access for the WiSE System and builds on the momentum of our U.S. rollout. It is also a signal that WiSE reimbursement supports adoption across larger networks.

EBR is currently active in two HCA sites, St David's Medical Center in Austin, Texas and Medical City in Fort Worth, Texas. 

According to the release, this agreement will streamline the procurement and contracting pathways for the WiSE System across HCA Healthcare hospitals. 

EBR sales reps will be able to engage directly with physicians and administrators at HCA sites to support the continued adoption of the WiSE System. 

Morgans retains its buy recommendation

Following the announcement, the team at Morgans released updated guidance on the ASX biotech stock. 

We believe the agreement not only should support more efficient procurement and contracting processes, building on US commercial momentum following strong 1Q implant growth, but also reinforce management's recent commentary around increasing engagement with large IDNs and GPOs, which we view as critical to scaling adoption over time.

We continue to view EBR favourably given growing physician enthusiasm, expanding reimbursement support, increasing repeat utilisation and emerging evidence of institutional validation.

The broker retained its buy recommendation and $2.47 price target. 

From yesterday's closing price of just over 59 cents, this indicates an upside potential of more than 300%. 

Morgans isn't the only broker tipping exponential growth. 

As James Mickleboro reported yesterday, Bell Potter has also tipped 250% upside for this ASX biotech stock. 

The post With potential upside of more than 300%, is this ASX biotech the best buy on the ASX right now? appeared first on The Motley Fool Australia.

That's the view of analysts at Bell Potter, who believe this ASX biotech stock could rocket from current levels.

What is this ASX biotech stock?

EBR Systems is a clinical-stage company that has developed a patented Wireless Stimulation Endocardially (WiSE) technology.

This is for the treatment of cardiac rhythm disease and to eliminate the need for cardiac pacing leads when delivering cardiac resynchronisation therapy.

Bell Potter was pleased with the company's performance in the first quarter. And while its cash burn increased, it notes that this relates to large one-off items, so isn't concerned. It said:

The headline data had been pre-released which showed that sales doubled qoq, while unit volumes, ASP, hospital contracts signed and physicians trained, all heading in the right direction. All hospital contracts are continuing to be priced at the maximum rate of c.US$63k. Reported gross margins were at a relatively low c.7.8% given the early commercialisation phase, use of old inventory and use of the old manufacturing facility. If current inventory prices were used, the gross margin would have been c.- 25.4%. EBR expect to be in the new facility by the end of 3Q26, from which time gross margins should begin to increase through the combination of new automated machinery to drive efficiency in manufacturing, and scale.

The Adj. EBITDA loss of c.- US$15.1m v c.-US$9.2m pcp reflects the scale up of commercial operations. Operating Cash Outflow of c.-US$20.2m reflected one-off items including bonuses, payroll tax, demo and design units, as well as front loading of leasehold improvements (c.US$2.6m), which will be reimbursed by the landlord in the June quarter. Even allowing for the one-off items, EBR is still hovering at around two quarters of cash / cash equivalents remaining.

Big potential returns

According to the note, in response to the update, Bell Potter has retained its buy rating and $2.00 price target on the ASX biotech stock.

Based on its current share price of 57.5 cents, this implies potential upside of approximately 250% over the next 12 months.

Bell Potter believes it is just its funding question that is holding back its shares. Once resolved, the broker believes its shares could rally. It explains:

No change to earnings / valuation. Given the expectation of a further c.US$15m in revenue over the balance of CY26, we expect 1Q26 to be the peak in operating losses. Once the funding question is resolved, which has been impeding investor sentiment, we would expect the share price to rally.

The post Broker says this ASX biotech stock could rocket 250% appeared first on The Motley Fool Australia.

The ASX small-cap stock has developed its patented Wireless Stimulation Endocardially (WiSE) technology for the treatment of cardiac rhythm disease and to eliminate the need for cardiac pacing leads when delivering cardiac resynchronisation therapy.

What did EBR Systems report?

Last week, its release revealed a strong Q1 2026 growth in commercial cases.

It also said its WiSE® System was successfully implanted in 41 commercial patients during the quarter, bringing total implants across the pilot phase and Limited Market Release to 71. 

John McCutcheon, EBR Systems' President & Chief Executive Officer said in Q1 2026, the company made impressive progress across both commercial and clinical programs. 

Case volumes increased strongly during the quarter, reflecting growing physician experience, expanding site readiness and the steady execution of our Limited Market Release. 

We also continued to advance important clinical initiatives, with further enrolment in both the WiSE-UP post-approval study and the TLC-AU feasibility study, helping to expand the body of evidence supporting the WiSE System across a broader patient population.

This news prompted positive share price movement to end last week, with EBR Systems shares closing at $0.67. 

Bell Potter's buy recommendation and recent price target of $2.00 following this release indicates a potential upside of roughly 194%. 

Following this report, the team at Morgans also provided an updated outlook on EBR Systems shares. 

Momentum building

In a note out of the broker last Friday, Morgans said 1Q26 delivered a step-change in commercial execution, with 41 implants (+128% q/q) and preliminary revenue of US$2.25-2.36m, materially ahead of prior run-rate. 

Importantly, growth is being driven by repeat usage, not just new site additions, with the majority of 1Q implants coming from existing centres, supporting confidence in utilisation and scalability.

Morgans also said leading indicators remain strong, with 37 purchasing agreements, 55 physicians trained, and double-digit physician training demand, alongside with emerging multi-site IDN/GPO contracts. 

Buy recommendation in tact 

Morgans also noted that commercial bottleneck remains execution (sales capacity and contracting), not demand, with patient backlogs building and physician engagement "very high". 

We make no changes to CY26-28 forecasts or A$2.47 DCF-based valuation. BUY.

From last week's closing price of $0.67, this target indicates an estimated upside of approximately 268%. 

The post It could be time to buy-low on this ASX small-cap stock according to brokers appeared first on The Motley Fool Australia.

The S&P/ASX 200 Health Care Index (ASX: XHJ) has fallen almost 17% year to date. 

However, there are opportunities to find value for investors. 

Let's look at three ASX healthcare shares drawing positive outlooks from experts. 

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic ('theranostic') products using targeted radiation. 

This process treats cancerous or diseased cells, an alternative approach to many cancer therapies, which also attack healthy tissue at the same time.

Telix shares have rebounded over the past couple of months, rising 55% since mid February. 

Telix shares rose in March largely because several value-driving catalysts hit at once, improving both fundamentals and investor sentiment.

However, they remain down 48% over the last year. 

In good news for investors, brokers are expecting Telix shares to recover even further. 

Recently, Bell Potter retained its buy rating and $19 price target on this radiopharmaceuticals company's shares. 

From yesterday's closing price of $13.64, this indicates a further upside of roughly 39%. 

Mayne Pharma Group Ltd (ASX: MYX)

Mayne Pharma Group is another ASX healthcare stock that is down significantly from yearly highs. 

It has fallen 32% year to date. 

This includes a 6% decline yesterday, as investors may have reacted negatively to fresh tariff worries.

However, the company is confident the new tariffs will have "no material impact" on its FY27 earnings profile.

The stock price closed yesterday at $2.16, and after the recent fall, it may be another value play.

Two analysts' forecasts via TradingView have an average one-year price target of $5.75 on the stock, indicating more than 160% upside. 

EBR Systems Inc (ASX: EBR)

EBR Systems Inc is engaged in treatment for patients suffering from cardiac rhythm diseases by developing therapies using wireless cardiac stimulation. 

The company's Wise CRT System uses proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart.

It is down roughly 30% year to date. However, it is also drawing positive ratings from brokers. 

Yesterday, the company released a preliminary version of its operating metrics. 

The report showed strong Q1 2026 growth in commercial cases.

This prompted Bell Potter to release updated guidance on this ASX healthcare stock along with a price target of $2, indicating a potential 194% rise. 

The post Where is the value amongst ASX healthcare shares? appeared first on The Motley Fool Australia.

EBR is a clinical stage company that has developed its patented Wireless Stimulation Endocardially (WiSE) technology for the treatment of cardiac rhythm disease and to eliminate the need for cardiac pacing leads when delivering cardiac resynchronisation therapy. 

The healthcare stock rose roughly 7% yesterday after the company released an announcement to the ASX.

What did EBR systems announce?

Yesterday, the ASX healthcare stock released a preliminary version of its operating metrics earlier than scheduled by its quarterly reporting time frame (mid-May). 

According to Bell Potter, it is no surprise EBR has provided an early release as it gears up toward an eventual and large capital raising.

In yesterday's report, the company said it saw strong Q1 2026 growth in commercial cases. 

It reported: 

• Robust commercial momentum continued through Q1 2026 with case volumes more than doubling from Q4 2025
• The WiSE® System was successfully implanted in 41 commercial patients during the quarter, bringing total
• implants across the pilot phase and Limited Market Release to 71
• EBR expects to report revenue in the range of US$2.25M to US$2.36M for Q1 2026, based on preliminary unaudited quarter-end results and subject to quarter-end closing adjustments. 

John McCutcheon, EBR Systems' President & Chief Executive Officer said: 

In Q1 2026, we made impressive progress across both our commercial and clinical programs. Case volumes increased strongly during the quarter, reflecting growing physician experience, expanding site readiness and the steady execution of our Limited Market Release. We also continued to advance important clinical initiatives, with further enrolment in both the WiSE-UP post-approval study and the TLC-AU feasibility study, helping to expand the body of evidence supporting the WiSE System across a broader patient population. We are encouraged by the momentum we are seeing and remain focused on disciplined execution, physician training, site activation and building the clinical and commercial foundation for broader adoption of the WiSE System.

What did Bell Potter have to say?

Following the release, the team at Bell Potter released updated guidance on the ASX healthcare stock. 

The broker said the data continues to impress, with implants more than doubling to quarter of quarter to 41.

The success in implant volume is supported by the growing breadth of physicians trained and hospital contracts signed. A further 22 Physicians trained on the WiSE pacing system and 16 hospital contracts signed in the quarter, bringing the cumulative totals to 55 & 37. EBR appear be tracking well toward our hospital target of 60 for FY26.

Big upside for this ASX healthcare stock

Bell Potter has maintained its buy recommendation for EBR Systems, along with a price target of $2.00. 

From yesterday's closing price of $0.68, that indicates a potential upside of 194%. 

It is not surprising that the market has reacted well to the data release, and with each data release we grow more confident in EBR's commercial prospects and expect the market to do so as well.

The post Bell Potter says this ASX healthcare stock could rise nearly 200% appeared first on The Motley Fool Australia.

Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:

Bendigo and Adelaide Bank Ltd (ASX: BEN)

The Bendigo and Adelaide Bank share price is up 8% to $11.33. This morning, the regional bank revealed the second phase of the Productivity Program to accelerate its progress towards its 2030 strategy. This includes a seven-year technology service partnership with Infosys (NYSE: INFY), which will significantly improve its IT service delivery capability and provide access to enhanced capabilities, software engineering, and AI talent to deliver greater capacity to innovate. These changes are expected to result in an annual run rate expense benefit of approximately $65 million to $75 million, which will be realised by FY 2028. In addition, it released a trading update which revealed unaudited cash earnings of $137.9 million during the third quarter. This is up 7.6% on the quarterly average during the first half.

EBR Systems Inc (ASX: EBR)

The EBR Systems share price is up 7% to 70.5 cents. This follows the release of a first-quarter update from the medical device company this morning. EBR advised that it expects to report revenue in the range of US$2.25 million to US$2.36 million for the first quarter of 2026. The company's CEO, John McCutcheon, said: "In Q1 2026, we made impressive progress across both our commercial and clinical programs. Case volumes increased strongly during the quarter, reflecting growing physician experience, expanding site readiness and the steady execution of our Limited Market Release."

Strickland Metals Ltd (ASX: STK)

The Strickland Metals share price is up 9% to 23.5 cents. This has been driven by the release of positive assay results from diamond drilling at the Obradov Potok prospect in the Rogozna Project, Serbia. Strickland Metals' managing director, Paul L'Herpiniere, commented: "Following recent discoveries at Red Creek and Kotlovi, these results continue to highlight the scale and endowment of the broader Rogozna system. We are looking forward to undertaking follow-up drilling as part of the 2026 field season targeting the interpreted core of the system at Obradov Potok, where we see a compelling opportunity to make a major new discovery."

Woodside Energy Group Ltd (ASX: WDS)

The Woodside Energy share price is up 4% to $33.27. This is despite there being no news out of the energy giant on Thursday. However, it is possible that investors believe Woodside shares were oversold yesterday after oil prices sank in response to the reopening of the Strait of Hormuz.

The post Why Bendigo Bank, EBR Systems, Strickland, and Woodside shares are rising today appeared first on The Motley Fool Australia.

It's important for investors not to panic, as history shows the market will recover. 

When markets fall, it does create buying opportunities for investors. 

For those looking to monitor small-caps or penny stocks, here are three that have drawn positive outlooks from brokers. 

Paragon Care Ltd (ASX: PGC)

Paragon Care conducts its business largely within the Australian healthcare sector and in 7 countries across Asia. The core business is distribution of pharmaceutical medicines, consumables and capital products. 

Following earnings results released last week, the team at Bell Potter released updated guidance on the healthcare stock.

The broker said it is cautiously optimistic on the full year EBITDA. 

It said the two cornerstones of long term earnings growth for Paragon are the expanding footprint in Medical Technology particularly in Asia and the expanding footprint in pharmacy distribution. 

At the recent half year result Asia Med Tech revenues grew 33% at gross profit margin of 45%. In the pharmacy wholesale business, the underlying growth rate (which excludes Infinity group trading from the prior period) was ~6%. The company estimates it has ~10% market share currently with aspirations to grow to 15%.

Included in the report from Bell Potter was a buy recommendation and price target of $0.30. 

This indicates a potential upside of 46% for this penny stock from yesterday's closing price. 

EBR Systems Inc (ASX: EBR)

EBR systems is another penny stock drawing a positive outlook from Bell Potter. 

The company is primarily engaged in treatment for patients suffering from cardiac rhythm diseases by developing therapies using wireless cardiac stimulation. 

The Wise CRT System uses proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart.

Following recent earnings results, Bell Potter adjusted its outlook on this penny stock, including a revised price target of $2.00. 

The broker maintained its buy recommendation. 

EBR systems closed trading yesterday at $0.58. 

Airtasker Ltd (ASX: ART)

This ASX penny stock is an online platform that connects people wanting to outsource tasks with people who are willing to do them for a fee. 

Typical tasks include home cleaning, removal services, handyman jobs, admin work, photography, graphic design, and collection services.

It closed trading yesterday at $0.22, however it has attracted a buy rating and $0.51 price target from Morgans after it posted healthy half-year results last month. 

The post 3 ASX penny stocks drawing positive ratings from experts appeared first on The Motley Fool Australia.

That's the view of analysts at Morgans, who believe this ASX stock could be dirt cheap following recent weakness.

What is this ASX stock?

EBR Systems is a Silicon Valley-based medical device company focused on the treatment of cardiac rhythm disease through wireless cardiac pacing.

The ASX stock's patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads.

This is a big deal as historically cardiac pacing leads have been a major source of complications, effectiveness, and reliability issues in cardiac rhythm disease management.

Its initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products will potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

What is Morgans saying?

Morgans was pleased with the company's progress in 2025, highlighting that the year saw a "pivotal transition to commercialisation."

It was also pleased to see that strong early momentum has continued into 2026. This is being supported by favourable reimbursement and growing physician engagement.

Commenting on the company, the broker said:

CY25 marked a pivotal transition to commercialisation, with first US implants and strong early momentum continuing into CY26, supported by favourable reimbursement and growing physician engagement. Early KPIs remain encouraging, with implant volumes accelerating (18 in 4Q; 25 in Jan–Feb CY26), 28 hospital agreements signed, and 46 physicians trained, indicating a solid foundation for scale.

Salesforce capacity and reimbursement complexity, not demand, act as governors, with strong patient pipelines and high physician enthusiasm. With cash of cUS$54m, B/S is a near-term focus, placing increased importance on execution through CY26 to support future funding at improved terms.

Big potential returns

According to the note, the broker sees potential for some mouth-watering returns over the next 12 months.

In response to its recent update, Morgans has retained its buy rating on the ASX stock with a trimmed price target of $2.47 (from $2.95).

Based on its current share price of 64 cents, this implies potential upside of approximately 285% for investors between now and this time next year.

To put that into context, a $2,000 investment would turn into approximately $7,700 if Morgans is on the money with its recommendation.

The post Guess which ASX stock could more than triple in value according to Morgans! appeared first on The Motley Fool Australia.

EBR Systems is engaged in treatment for patients suffering from cardiac rhythm diseases by developing therapies using wireless cardiac stimulation. The company's Wise CRT System uses proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart.

What did the company announce?

Yesterday, the company released a Quarterly Cash Flow Report for the quarter ended 31 December 2025.

Key highlights included: 

• Successful A$79.5m capital raise completed in Q2 2025, with EBR well-capitalised through to in initial commercialisation. 
• 4Q25 revenue of approximately US$1.6m (ahead of estimates from Bell Potter). 
• Gross margin of approximately 30%, supported by lower-cost legacy R&D inventory. 

John McCutcheon, EBR Systems' President & Chief Executive Officer said:

2025 marked a defining year for EBR as we successfully transitioned from a development-stage company to a commercial medical device business. Achieving FDA approval for the WiSE® CRT System in April and initiating our U.S. commercial launch were transformational milestones that position EBR at the forefront of leadless cardiac resynchronisation therapy.

The company has seen its share price tumble more than 20% this year, however investors will be hoping yesterday's announcement could be the beginning of a turnaround, after the share price climbed 1.45% during Thursday.

What did Bell Potter have to say?

Following the report, the team at Bell Potter issued updated guidance on this ASX small-cap. 

The broker said operating metrics are trending well. 

The 4Q25 data showed implants doubled to 18 and 30 for FY25. Data released to February, suggests implant volume could double again.

Bell Potter said hospital contracts and physician training are ahead of schedule, with 21 contracts signed in FY25 (28 quarter-to-date) and 33 physicians trained in FY25 (46 QTD), indicating strong future demand as physician readiness is outpacing hospital onboarding. 

While progress is solid, short-term growth is being modestly constrained by early-stage challenges such as sales team ramp-up and hospitals learning to administer and code the WiSE procedure, which appear to be temporary during this limited market release phase.

Buy recommendation in tact 

Bell Potter maintained its buy recommendation but lowered its price target to $2.00 (previously $2.43). 

Reflecting on training and hospital administration issues, we have adjusted our estimates across the forecast period. We have reduced our unit volume estimates by c.32.8% / c.37.5% / c.33.5% for FY26e-FY28e.

From yesterday's closing price of $0.70, the broker sees an estimated upside of 186% on this ASX small-cap stock.

The post Bell Potter is tipping this ASX small-cap to double in the next year appeared first on The Motley Fool Australia.

Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:

EBR Systems Inc (ASX: EBR)

The EBR Systems share price is up 4% to 72 cents. This follows the release of the medical device company's quarterly update. EBR Systems' president and chief executive officer, John McCutcheon, was pleased with the progress the company is making. He said: "2025 marked a defining year for EBR as we successfully transitioned from a development-stage company to a commercial medical device business. Achieving FDA approval for the WiSE CRT System in April and initiating our U.S. commercial launch were transformational milestones that position EBR at the forefront of leadless cardiac resynchronisation therapy."

Electro Optic Systems Holdings Ltd (ASX: EOS)

The EOS share price is up a further 3% to $10.01. This defence and space company's shares have been rebounding after a major sell-off on Tuesday. The catalyst for this was news that the company's CEO, Dr Andreas Schwer, was given approval to sell 2.5 million EOS shares on-market following the exercise of options that were granted under a long-term incentive plan. Some investors may believe the selling was an overreaction, especially after its CEO committed to retain a shareholding well above the minimum levels required under its recently announced shareholding policy.

Racura Oncology Ltd (ASX: RAC)

The Racura Oncology share price is up 21% to $2.89. Investors have been buying this oncology company's shares after it announced the successful dosing of a patient in Hong Kong with its RC220 cancer compound. Importantly, there has been no vein inflammation or other adverse events reported following the dosing. Racura's CEO, Dr Daniel Tillett, said: "The safe dosing of the third patient in our RC220 solid tumour trial in Hong Kong and recruitment of the first dose escalation cohort is an important milestone for Racura Oncology. We are grateful to all the patients, investigators, and clinical teams who have made this trial possible and we look forward to treating patients on the updated protocol."

Woodside Energy Group Ltd (ASX: WDS)

The Woodside Energy share price is up 6% to $33.44. This has been driven by another rise in oil prices overnight amid concerns over the impact of the war in the Middle East on supplies. It isn't just Woodside that is rising today. The S&P/ASX 200 Energy index is up 4.9% at the time of writing.

The post Why EBR, EOS, Racura, and Woodside shares are rising today appeared first on The Motley Fool Australia.

Here are three of them, all tipped to climb by more than 100% in the next 12 months!

WiseTech Global (ASX: WTC) 

The WiseTech share price is 1.94% higher in Tuesday afternoon trade. At the time of writing, the shares are changing hands for $63.09 each. That's a 7.99% decline for the year so far, and a huge 47.28% below where the stock was trading at this time last year.

A number of headwinds have put the logistics software provider's stock under pressure in 2025, but WiseTech still has strong growth potential ahead of it this year.

The business is strong; it is continually expanding its operations and has a proven track record of company growth, even amid volatility. 

Analysts are incredibly bullish about the outlook for the tech shares. TradingView data shows that 12 out of 14 have a strong buy rating on the stock, and another has a buy rating. The maximum target price is $175.65, which implies the shares could jump a whopping 178.28% this year, at the time of writing.

EBR Systems Inc (ASX: EBR)

EBR Systems is a Silicon Valley-based medical device company that has developed Wireless Stimulation Endocardially (WiSE®) technology. It is the world's only wireless, leadless left ventricular pacing device for heart failure patients.

The technology helps to treat individuals with cardiac rhythm diseases by sending electrical stimulation directly to the heart. It conducts operations in the US, but it's primary listing is on the ASX.

At the time of writing, its shares are down 3.19% to 91 cents each. It means the shares are now 48.59% below where they were this time last year.

The Australian stock has reached some excellent milestones over the past year, including the first implant of its WiSE technology and strong Q4 FY25 commercial and clinical progress. 

Analysts are bullish on the outlook of EBR Systems in 2026. TradingView data shows all four analysts have a strong buy rating, with a maximum target price of $2.97 a piece. That implies a potential 226.12% upside at the time of writing. Even the minimum target price of $2.43 implies a potential 167.32% upside in 2026.

Zip Co Ltd (ASX: ZIP)

Zip shares have had a disappointing start to 2026 so far. The shares are down 2.14% today to $2.98 a piece. For the year to date, the stock has dropped 11.19% and it's now 5.08% below this time last year.

But I think the latest decline represents a great opportunity for investors to get into high-quality stock at a cheap price.

Zip has posted some strong financial results over the past few quarters, and the business has some great growth plans in place for 2026. 

The company is expected to post its FY26 half-year results in February, at which point investors will find out if the company is still on track. Good news could push the share price higher over a short period of time. I think the stock is a screaming buy for 2026.

Analysts are optimistic too. TradingView data shows that 9 out of 11 analysts have a buy or strong buy rating on the stock. The maximum target price is $6.72, which, at the time of writing, implies a potential 126.26% upside ahead over the next 12 months. 

The post 3 Australian stocks tipped to grow 100% (or more) in 2026 appeared first on The Motley Fool Australia.

Three that it has given its verdict on are revealed below. Is it bullish, bearish, or something in between? Let's find out:

Baby Bunting Group Ltd (ASX: BBN)

Morgans has become more positive on this baby products retailer's shares following recent weakness.

And while it isn't quite ready to recommend Baby bunting as a buy, it has lifted its rating to hold (from trim) with a $2.70 price target. Commenting on the ASX share, the broker said:

The recent share price pullback has provided an opportunity to move our recommendation to HOLD (from TRIM), now offering ~6% TSR to our unchanged target price. Refurbished stores to date have performed above our expectations and management's target range (15-25%).

Up to October, the 3 refurbished stores have seen sales up 30% on the pcp. BBN has now completed 9 refurbishments, and we expect BBN to provide an update on performance at the 1H26 result. We see the risk/ reward now more balanced, and 14x FY27 PE as a fair valuation. We have made no changes to our forecasts or valuation. We have a $2.70 price target.

EBR Systems Inc (ASX: EBR)

An ASX share that Morgans is more positive on is EBR Systems. It is a medical device company focused on the treatment of cardiac rhythm disease through wireless cardiac pacing. It has a buy rating and $2.95 price target on its shares.

Morgans has been impressed with the company's commercial performance and highlights its sizeable total addressable market (TAM). It said:

4Q25 delivered a clear step-up in commercial execution, with case volumes doubling q/q and revenue materially ahead of expectations, confirming accelerating physician uptake during the Limited Market Release (LMR). Preliminary 4Q revenue of US$0.87-0.94m exceeded our estimate by c60%, with FY25 revenue of US$1.55-1.62m validating early pricing and demand assumptions.

We view clinical momentum with the WiSE-UP post-approval study and the TLC-AU feasibility study as supporting longer-term adoption and label expansion. Updated TAM of US$5.8bn (+60%) highlights a materially larger opportunity, underpinned by growth in leadless pacing and de novo CRT applications. We adjusted CY25-27 forecasts, with our DCF-based valuation increasing to A$2.95. BUY.

Treasury Wine Estates Ltd (ASX: TWE)

Finally, this wine giant's shares have fallen heavily over the past 12 months. Unfortunately, Morgans doesn't believe this necessarily means they are in the buy zone yet.

The broker has a hold rating and $5.25 price target on its shares. Commenting on the Penfolds owner, Morgans said:

As we feared, but even weaker than expected, TWE's trading update meant that consensus estimates were far too high. Its US performance was particularly disappointing given of all the capital spent in recent years. Gearing is now well above TWE's target range and will remain high for the next couple of years.

While we made large downgrades to our forecasts only two weeks ago following the goodwill write-down, TWE's new trading update has seen us make another round of material revisions. We stress that earnings uncertainty remains high. It will take time for new management to deliver more acceptable returns and for TWE to rebuild credibility with the market. We maintain a HOLD rating.

The post Buy, hold, sell: Morgans gives its verdict on 3 ASX shares appeared first on The Motley Fool Australia.

Three ASX shares that brokers have named as buys this week are listed below. Here's why their analysts are feeling bullish on them right now:

Computershare Ltd (ASX: CPU)

According to a note out of Citi, its analysts have upgraded this share registry company's shares to a buy rating with a trimmed price target of $39.60. The broker believes that recent share price weakness means that the risk is now skewed to the upside for investors. Especially given its belief that increased mergers and acquisitions, initial public offerings, and debt issuance activity could offset softer margin income. And while it has trimmed its earnings per share forecasts to reflect interest rate cuts, it sees plenty of value on offer with its shares at current levels. The Computershare share price is trading at $34.40 on Wednesday afternoon.

EBR Systems Inc (ASX: EBR)

A note out of Morgans reveals that its analysts have retained their buy rating on this medical device company's shares with an improved price target of $2.95. Morgans highlights that EBR Systems delivered a clear step-up in commercial execution during the fourth quarter. This includes volumes doubling quarter on quarter and revenue coming in materially ahead of expectations. It believes this confirms an accelerating physician uptake. In addition, the broker views clinical momentum with the WiSE-UP post-approval study and the TLC-AU feasibility study as supporting longer-term adoption and label expansion. So much so, its updated total addressable market has increased by 60% to US$5.8 billion, giving the company a materially larger opportunity. This is being underpinned by growth in leadless pacing and de novo CRT applications. The EBR Systems share price is fetching $1.11 at the time of writing.

Mineral Resources Ltd (ASX: MIN)

Analysts at Bell Potter have retained their buy rating on this mining and mining services company's shares with an increased price target of $68.00. Looking ahead to its quarterly update, the broker is expecting a small decline in iron ore production, slightly higher costs, and steady lithium production. However, due to significantly better than expected commodity prices, the broker has boosted its earnings estimates and valuation materially. In addition, it highlights that Mineral Resources is positioned to benefit from a recovery in lithium markets, with around 338ktpa of offline spodumene production capacity. The Mineral Resources share price is trading at $60.44 today.

The post Top brokers name 3 ASX shares to buy today appeared first on The Motley Fool Australia.

Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising today:

EBR Systems Inc (ASX: EBR)

The EBR Systems share price is up 5% to $1.10. Investors have been buying this medical device company's shares following the release of a bullish broker note out of Morgans. According to the note, the broker has retained its buy rating on EBR Systems' shares with an improved price target of $2.95. It said: "We view clinical momentum with the WiSE-UP post-approval study and the TLC-AU feasibility study as supporting longer-term adoption and label expansion. Updated TAM of US$5.8bn (+60%) highlights a materially larger opportunity, underpinned by growth in leadless pacing and de novo CRT applications."

Endeavour Group Ltd (ASX: EDV)

The Endeavour Group share price is up 2.5% to $3.79. This may have been driven by the release of a broker note out of Citi. According to the note, the broker has upgraded the drinks giant's shares to a buy rating with an improved price target of $4.10. It was pleased with improving sales trends reported by the Dan Murphy's and BWS owner, but acknowledges that its earnings have fallen short of expectations due to margin weakness.

Monadelphous Group Ltd (ASX: MND)

The Monadelphous share price is up 2.5% to $29.34. Investors have been buying this diversified services company's shares after it announced another new contract win. Monadelphous has been awarded a major long-term maintenance contract with Rio Tinto Ltd (ASX: RIO) worth approximately $300 million over five years. Monadelphous' managing director, Zoran Bebic, said: "We are delighted to continue supporting Rio Tinto's Pilbara iron ore operations, where Monadelphous has provided services for more than 30 years."

Neuren Pharmaceuticals Ltd (ASX: NEU)

The Neuren Pharmaceuticals share price is up 7% to $20.71. This follows the release of a sales update from the pharmaceuticals company this morning. Neuren revealed that its US partner now believes global sales could reach about US$700 million by 2028. This will be a big increase on its 2025 guidance of US$400 million. Supporting this is the continued momentum it is experiencing, with more than 2,000 Rett patients treated by Daybue since US launch. There are an estimated 6,000 sufferers in the US.

The post Why EBR Systems, Endeavour, Monadelphous, and Neuren shares are racing higher today appeared first on The Motley Fool Australia.

In fact, the S&P/ASX 200 Health Care (ASX:XHJ) index is down more than 24% over the last 12 months. 

For context, the S&P/ASX 200 Index (ASX: XJO) is up 7.5% in that same span. 

One of the many healthcare stocks have stumbled in the last year is EBR Systems Inc. (ASX: EBR). 

Its share price has fallen by 20% in that time.

However it has drawn an attractive buy recommendation and valuation from the team at Morgans. 

Let's find out what's behind the positive outlook. 

Introducing EBR Systems

EBR Systems is a medical technology company that develops innovative, implantable cardiac pacing devices designed to treat cardiac rhythm diseases, especially heart failure.

Its' key technology is the Wireless Stimulation Endocardially (WiSE) technology, which was developed to eliminate the need for cardiac pacing leads.

Back in December, the company made headlines due to successfully implanting the first patient in a key clinical trial.

The company behind this healthcare stock said:

The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

Commercial and Clinical Progress

In its Q4 announcement released on Monday, the company said the WiSE System was implanted in 18 commercial patients during Q4 2025, doubling the number performed in Q3 2025.

The company also said it expects to report revenue in the range of US$870K and US$935K for Q4 2025, and total 2025 revenue in the range of US$1,552K and $1,617K, based on preliminary unaudited year-end results and subject to yearend closing adjustments. 

John McCutcheon, EBR Systems' President & Chief Executive Officer said:

In Q4 2025, we continued to make solid progress across both our commercial and clinical programs. Case volumes increased meaningfully, reflecting growing physician experience and expanding site readiness. Additionally, we advanced important clinical initiatives, including the commencement of the WiSE-UP post-approval study and the first patient enrolled and implanted in the TLC-AU feasibility study.

What's Morgans' view?

In a note out of Morgans yesterday, the broker said 4Q25 delivered a clear step-up in commercial execution, with case volumes doubling q/q and revenue materially ahead of expectations, confirming accelerating physician uptake during the Limited Market Release (LMR). 

Preliminary 4Q revenue of US$0.87-0.94m exceeded its estimate by c60%, with FY25 revenue of US$1.55-1.62m validating early pricing and demand assumptions. 

We view clinical momentum with the WiSE-UP post-approval study and the TLC-AU feasibility study as supporting longer-term adoption and label expansion. Updated TAM of US$5.8bn (+60%) highlights a materially larger opportunity, underpinned by growth in leadless pacing and de novo CRT applications.

The broker has adjusted CY25-27 forecasts, with its DCF-based valuation increasing to $2.95. 

This updated price target indicates an upside of more than 180% from yesterday's closing price of $1.05. 

The post Top broker says this ASX small-cap healthcare stock could be set to double appeared first on The Motley Fool Australia.

The company told the ASX in a statement that the first patient had been enrolled and implanted in the "totally leadless CRT" study being carried out at the Princess Alexandra Hospital in Brisbane.

Groundbreaking technology

EBR's key technology is the Wireless Stimulation Endocardially (WiSE) technology, which was developed to eliminate the need for cardiac pacing leads.

The company said in its statement that such leads were "historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management''.

It went on to say:

The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

The first implant procedure announced to the ASX on Friday was carried out the day before by electrophysiologist Dr Paul Gould.

The company said the new study would build on previous work and potentially open up a much larger addressable market.

Totally Leadless CRT, pairing EBR's WiSE System with a leadless right ventricle pacemaker, has been previously published, and is already included in the FDA-approved labelling for patients with an existing leadless pacemaker who subsequently develop pacing-induced heart failure and require an upgrade to CRT. The TLC-AU study will build on this previous published experience by treating newly diagnosed heart failure patients requiring CRT. These de novo patients will receive a leadless pacemaker and the WiSE System. De novo patients account for around 75% of the CRT market, meaning this indication has the potential to significantly expand EBR's total addressable market and establishing WiSE as a potential first-line option for patients requiring CRT.   

EBR president John McCutcheon said it was a significant achievement for the company.

He went on to say:

The first implant in the TLC-AU Study is a significant milestone for EBR, marking our entry into the much larger frontline CRT market. TLC-AU allows us to build on the FDA labelled upgrade indication and generate the evidence needed to position WiSE CRT as a fully leadless alternative for patients requiring resynchronisation therapy. As leadless pacing rapidly becomes standard of care, advancing a totally leadless CRT solution strengthens EBR's leadership in the next major evolution of heart-failure treatment.

EBR shares were 3.3% higher in early trade at 93.5 cents. The shares have traded as high as $2.08 over the past year and currently are not far off their 12-month lows of 86 cents.

The company was valued at $407.3 million at the close of trade on Thursday.

The post Biotech company implants heart device in world first appeared first on The Motley Fool Australia.